Leuprorelin acetate - Precocious puberty
You are here : Home > Formulary Search > Leuprorelin acetate - Precocious puberty
Documentation
PAD Profile
See PAD entry for current shared care document "Precocious puberty"
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
Committee Recommendations (2)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated shared care for the treatment of Precocious Puberty and the PIL to support children and their families
During the process of reviewing drugs for inclusion on the Surrey Heartlands Joint Formulary, it was noted that Leuprorelin had not been included within the shared care arrangements for treatment of precocious puberty.
Leuprorelin did not have a license for this indication at the point of agreeing shared care for triptorelin.
Leuprorelin is now licensed for precocious puberty and can be used in accordance with the shared care agreement.
The shared care document will be reviewed and updated.
Other Indications
Below are listed other indications that Leuprorelin acetate is used to treat.